Skip to main content
Quest Diagnostics

Clinical and Economic Outcomes of a Pharmacogenomics-Enriched Comprehensive Medication Management Program in a Self-Insured Employee Population

Clinical and Economic Outcomes of a Pharmacogenomics-Enriched Comprehensive Medication Management Program in a Self-Insured Employee Population

Authors: Fragala MS, Keogh M, Goldberg SE, Lorenz RA, Shaman JA

Citation: Pharmacogenomics J. 2024 Oct 2;24(5):30. doi: 10.1038/s41397-024-00350-1.

Specialties: Genetics, Neurology, Prescription Drug Monitoring, Toxicology, Population Health

 

 

 

 

 

Related content

On-Demand Webinar
Current state of Pharmacogenomics and its future
Publication
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
Publication
Early insights from a pharmacogenomic-enriched comprehensive medication management program implementation in an adult employee population
Audio Podcast
Pharmacogenomics in Mental Health and Addiction

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.